OPT2MISE was a prospective, randomised, controlled, parallel group study aiming to evaluate the comparative efficacy of MDI regimens in insulin-using patients with T2D, suboptimally controlled with advanced basal-bolus therapy.17 A total of 35 centres participated, including eight in Canada, 20 in Europe and Israel and three in the US. The gene discussed is INS; the disease is type 2 diabetes mellitus.